Search results
Results from the WOW.Com Content Network
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers.The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry.
The targets and drugs in TTD cover 583 protein biochemical classes and 958 drug therapeutic classes, respectively. [1] The latest version of the International Classification of Diseases (ICD-11) codes released by WHO are incorporated in TTD to facilitate the clear definition of disease/disease class.
This is a list of notable medical and scientific journals that publish articles in pharmacology and the pharmaceutical sciences This is a dynamic list and may never be able to satisfy particular standards for completeness.
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell. Acute myeloid leukaemia
move to sidebar hide. From Wikipedia, the free encyclopedia
Bentham Open, its open access division, has received criticism for questionable peer-review practices as well as invitation spam; it was listed as a "potential, possible, or probable predatory scholarly open access publisher" in Jeffrey Beall's list of predatory publishers, [4] before the list went defunct.
Current Drugs was acquired by Thomson Corporation in 2004. [1] Journals in the series included: Current Opinion in Drug Discovery & Development (ISSN 1367-6733) Current Opinion in Investigational Drugs (ISSN 0967-8298), established in 1992 continued as Expert Opinion on Investigational Drugs in 1994; Current Opinion in Investigational Drugs ...
This version contained 1424 approved small molecule drugs and 132 biotech drugs as well as >4000 unique drug targets. Version 3.0 also included drug transporter data, drug pathway data, drug pricing, patent and manufacturing data as well as data on >5000 experimental drugs.